Navigation Links
ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
Date:8/5/2010

Cinryze is for intravenous use only. A dose of 1000 Units of Cinryze can be administered every 3 or 4 days for routine prophylaxis against angioedema attacks in HAE patients. Cinryze is administered at an injection rate of 1 mL per minute.

About Hereditary Angioedema (HAE)

HAE is a rare, severely debilitating, life-threatening genetic disorder caused by a deficiency of C1 inhibitor, a human plasma protein. This condition is the result of a defect in the gene controlling the synthesis of C1 inhibitor. C1 inhibitor maintains the natural regulation of the contact, complement, and fibrinolytic systems, that when left unregulated, can initiate or perpetuate an attack by consuming the already low levels of endogenous C1 inhibitor in HAE patients. Patients with C1 inhibitor deficiency experience recurrent, unpredictable, debilitating, and potentially life threatening attacks of inflammation affecting the larynx, abdomen, face, extremities and urogenital tract. Patients with HAE experience approximately 20 to 100 days of incapacitation per year. There are estimated to be at least 6,500 people with HAE in the United States.

For more information on HAE, visit the U.S. HAE Association's website at: www.haea.org.

About ViroPharma Incorporated

ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing innovative products for physician specialists to enable the support of patients with serious diseases for which there is an unmet medical need, and providing rewarding careers
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... N.J. , May 4, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... multiple countries worldwide, will report Q1 2015 financial ... 11, 2015.  CytoSorbents, management will ... that will recount both operational and financial progress ...
(Date:5/4/2015)... , May 4, 2015 /PRNewswire/ - YOLO ... the manufacturing and distribution of medical and aesthetic ... market clearance for YOLO,s new generation body contouring ... has completed its second-generation low-level laser device for ... advancements to our patented technology while continuing to ...
(Date:5/4/2015)... May 4, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or ... notification from the Food and Drug Administration ("FDA" or the ... March 31, 2015, has been placed on clinical hold pending ... related to the stability of the drug substance and drug ... The Company had sought approval of their IND application ...
Breaking Medicine Technology:CytoSorbents to Report Q1 2015 Operating and Financial Results 2CytoSorbents to Report Q1 2015 Operating and Financial Results 3YOLO Medical Inc. receives FDA clearance for body contouring laser 2ESSA Pharma Inc. Receives FDA Response on IND Application 2ESSA Pharma Inc. Receives FDA Response on IND Application 3ESSA Pharma Inc. Receives FDA Response on IND Application 4
... HONG KONG, Sept. 20, 2011 /PRNewswire-Asia/ -- Golden ... subsidiaries collectively as the "Group," - 801.HK; 910801.TW), a ... of 2.0% interest in FunTalk China Holdings Limited, the ... the Group,s effective interest in FunTalk China will be ...
... NEW YORK, September 20, 2011 Preetha ... the United Nations Summit at New York held by ... of Non-Communicable Diseases. Non-communicable diseases, such as ... disease, account for more than 63 percent of all ...
Cached Medicine Technology:Golden Meditech Disposes of 2.0% Stake in FunTalk China for US$15 Million 2Preetha Reddy, Managing Director, Apollo Hospitals Invited to United Nations Summit on NCDs 2
(Date:5/4/2015)... Dr. Benjamin Stong of Kalos Facial Plastic ... non-surgical double-chin eliminator. Dr. Stong is double board ... to offer Kybella treatments . The FDA recently ... the chin, promising to safely dissolve fat deposits and ... sought immediate solutions for their double chin were forced ...
(Date:5/4/2015)... Dr. Richard Champagne, DMD, MAGD is pleased to ... America’s Best Dentist Award, given by the National Consumer ... dentist is a reflection of his vast experience in ... for his patients. , Each year, the National Consumer ... field. These nominees are dentists who have exceptionally high ...
(Date:5/4/2015)... For partners who’d like to become parents, ... Astroglide TTC™ (Trying to Conceive) . Unlike traditional lubricants ... Astroglide TTC™ is specially formulated to provide a better ... for Disease Control, an average of one in ... a pregnancy, and over 7.4 million women ...
(Date:5/4/2015)... Washington, DC (PRWEB) May 04, 2015 ... (ACE) has just released the first-ever congenital ... Congenital Cardiac Catheterization Laboratory (PCCL) accreditation. Driven ... CHD standards are a comprehensive review of ... with congenital heart disease. , “The ACE ...
(Date:5/4/2015)... California (PRWEB) May 04, 2015 Sara ... a physician practice management firm in Los Angeles associated ... today the patent-pending status of The Sara Soulati Health ... Soulati in 2010, is a lifestyle modification and disease ... April 2015 to the U. S. Patents and Trademarks ...
Breaking Medicine News(10 mins):Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2
... tests separately predict the likelihood that a patient,s breast ... the cancer,s vulnerability to chemotherapy or hormone therapy, researchers ... Center report at the first American Society of Clinical ... Francisco. , Each predictor - of prognosis, of ...
... to headline Boston forums, BOSTON, Sept. 7 ... and former Republican,Governor Mike Huckabee (AR) will address ... 2007. (Logo: http://www.newscom.com/cgi-bin/prnh/20070209/NYF043LOGO ) ... AARP,s annual,member event. The candidates will address AARP,s ...
... PA, Sept. 7 /PRNewswire-FirstCall/ - MDS Pharma,Services, a ... has won the Good Clinical Practice Journal (GCPj) ... access to new medicines. This,award is one of ... year to,recognize excellence in clinical research. MDS Pharma ...
... hours of instruction improved relationships with patients, study claims ... evidence suggests that a bit of theatrics can help ... on the experience of a small group of internal ... workshops and lectures led by university theater professors. , ...
... October 16, 2007, SUNNYVALE, Calif., Sept. 7 ... has set October 16, 2007, as the,date of the ... with a wholly owned subsidiary of Medtronic. The ... Time, at,Kyphon,s corporate headquarters located at 1221 Crossman Avenue, ...
... LifeQuest World,Corporation (formerly PhytoLabs Inc.) announced today that the ... contest to allow the,public to participate in choosing a ... 30, 2007. The company was unable to use any ... prize of a trip for two to,Las Vegas was ...
Cached Medicine News:Health News:Microarray provides 3 genomic guides to breast cancer treatment decisions 2Health News:Microarray provides 3 genomic guides to breast cancer treatment decisions 3Health News:Microarray provides 3 genomic guides to breast cancer treatment decisions 4Health News:Presidential Candidates Address Health, Financial Security at AARP's Life@50+ 2Health News:MDS Pharma Services Wins Award for Management of Global Malaria Trial 2Health News:Theater Classes Help Docs' Bedside Manners 2Health News:Theater Classes Help Docs' Bedside Manners 3Health News:Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger 2Health News:Kyphon Announces Special Meeting Date to Vote on Proposed Medtronic Merger 3Health News:LifeQuest Announces End of Immunity Health Challenge Contest 2
Duckbill. 3.5 mm tip. Light curve....
4 mm x 9 mm tip....
6 mm wide tip. Gentle tapered blade. Designated most popular model or size....
9 mm wide tip. 35 mm from angle to tip....
Medicine Products: